Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 34 n° 316

Posts Tagged ‘vaccine’

Do vaccine mandates work?

Posted by fidest press agency su giovedì, 27 gennaio 2022

A new study by economists at Simon Fraser University in British Columbia suggests they do. In the week after the announcement of a vaccine requirement to enter bars, gyms and restaurants in Canadian provinces, the researchers found that first-dose vaccinations increased by 42% over the previous week and by 71% over two weeks. They estimated that 287,000 more people were vaccinated within six weeks as a result. They also found rises in vaccination rates once mandates were announced in France, Germany and Italy in the summer of 2021.Despite such evidence, arguments over compulsory covid-19 vaccination are raging across Europe. Austria is in the vanguard, having made vaccination obligatory for adults from February. Others may soon follow.Meanwhile, the Omicron variant continues its march around the world. It has now come to Mexico, a place that never really shut down.In America, the number of children in hospital with covid is rising fast. Rapid transmission and vaccination discrepancies are part of the explanation.In our Finance section, we examine how, as China’s economy slows, policymakers seek to revive growth. Pandemic lockdowns and crackdowns are taking their toll. Meanwhile, our data team shows how China stands alone in its attitude towards the pandemic—it is one of few countries one of few countries where, according to our normalcy index, everyday activity has receded in the past year.Scientists and health-care workers have been rightly lauded for their work battling covid. But what of those whose job it is to measure that work? In our Britain section, we look at how the number-crunchers at the Office for National Statistics rose to the challenge. By Zanny Minton Beddoes Editor-In-Chief The Economist

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Which vaccine is most effective against Delta?

Posted by fidest press agency su sabato, 20 novembre 2021

Which vaccine is the most effective against the Delta variant? The Economist has collected the largest set of vaccine results against the variant and found that vaccines continue to provide significant protection. The two mRNA vaccines, from Moderna and Pfizer-BioNtech, performed best, followed by the AstraZeneca jab.Puerto Rico, an American territory of 3.3m people about 1,000 miles (1,600km) south-east of Florida, is an unexpected success story in the fight against covid-19. How did an impoverished, battered island handle the pandemic better than the rest of America?In Europe, meanwhile, a wave of covid infections is moving through German-speaking countries—an alliance of anti-vaxxers and the far right is largely to blame.Our data team has been looking into how, in Britain, a botched covid test gave false negative results to users and led to thousands of extra cases. A new study has shown that each incorrect result led to 0.6-1.6 subsequent reported infections. Many animals besides humans can catch SARS-CoV-2—mink, white-tailed deer, cats and dogs have all become infected and able to transmit the virus. In our Science section, we examine how animals like these might become viral reservoirs that lie beyond the easy reach of medical science and monitoring. Even if there are no human cases of covid in an area, such animal reservoirs mean that SARS-CoV-2 may still be lurking, waiting to spill back into people. In The World Ahead: 2022, our data correspondent James Fransham discusses The Economist’s “normalcy index” and asks if pre-pandemic behaviour will ever return. Some changes—such as falls in office occupancy and cinema attendance—are here to stay. Our industry editor Simon Wright, meanwhile, predicts that international travel will get easier in 2022, but restrictions will remain. Cross-border travel will probably not recover to pre-covid levels until 2024. By Zanny Minton Beddoes Editor-In-Chief The Economist

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Why America needs vaccine mandates

Posted by fidest press agency su mercoledì, 22 settembre 2021

After months of begging Americans to get themselves vaccinated, President Joe Biden has stopped asking nicely. On September 9th the Biden administration announced a requirement to be vaccinated or tested regularly covering about 100m Americans. There are clear reasons for taking this unusual step. Only 54% of Americans are fully vaccinated, meaning the nation is lagging behind its peers. In a leader, we argue that Republican opposition to the vaccine mandate is fatally wrong-headed. The details of the Biden mandate could be improved on, but in democracies public health sometimes requires some coercion.Polls, meanwhile, show broad public support for the vaccine mandate—52% of adults approve whereas 40% disapprove.The mandate comes as covid-19 cases in American children are at an all-time high, raising the question of whether in-person schooling accelerates the spread of the virus.France tackled its vaccine hesitancy using covid-19 passports, which have proved efficient, and surprisingly popular.India’s pupils have been hard hit by extended school closures during the pandemic. Poverty, undernourishment and poor pedagogy make a bad situation worse.Britain is no longer at war with the coronavirus. Instead, it is working out how best to manage its presence. Its aim is to keep the economy open while saving hospitals from being overwhelmed. Vaccine passports, masks and working from home will be only back-up options. Another piece of good news is that vaccines seem to be holding up against the Delta variant—new data show that severe covid-19 is much rarer among vaccinated Britons. Zanny Minton Beddoes Editor-In-Chief The Economist

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Will America’s vaccine mandates work?

Posted by fidest press agency su martedì, 14 settembre 2021

A glance at the chart of global vaccine scepticism shows an alarming trend for Americans: while other rich countries see a steadily downward slope, America is flatlining. The highly contagious Delta variant continues its march across the country, wreaking exceptional havoc on the South, one of the country’s least-vaccinated regions. Even the filling up of local hospitals does not dent vaccine scepticism. Joe Biden is introducing vaccine mandates covering 100m people. But with legal challenges inevitable, the mandates face an uncertain fate.All through 2020 and the early part of this year, South-East Asia remained relatively unscathed by the pandemic. By the end of August, however, the region had recorded some 217,000 deaths from covid-19, about 2.6 times its total just three months earlier. The Delta variant has brought devastation.A big study in Bangladesh found simple ways to encourage mask use. Symptomatic infections of covid-19 went down as the use of masks went up.Our finance and economics writers look at the new economics of global cities. As national economies come back to life from the pandemic, cities are lagging seriously behind, as activity spreads outward from urban centres.In Britain, scientists have been purposely infecting volunteers with covid-19. In our Science section, we look at how such controversial “human challenge trials” may help answer important questions about the virus quickly.Our Bartleby columnist writes on how the pandemic has refashioned corporate dress codes. The Delta variant may be forcing companies to delay a return to the office, but when workers are eventually back at their desks, new sartorial rules may be required. Zanny Minton Beddoes Editor-In-Chief The Economist

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Which covid-19 vaccine is best for international travel?

Posted by fidest press agency su martedì, 27 luglio 2021

The Economist this week: Welcome to our weekly newsletter highlighting the best of our coverage of the pandemic and its effects.Perhaps the litmus test of the post-pandemic world will be how much international travel returns. But which covid-19 vaccine is the most widely accepted for international travel? A patchwork of complicated cross-border travel rules is causing confusion.England’s school year has staggered to a disappointing end. By the time schools began breaking up in mid-July, nearly a quarter of pupils were already absent, according to government figures.Meanwhile, the Delta covid-19 variant is ripping through Britain, with more than 40,000 cases reported a day (two-thirds of the peak in January). The decision by the prime minister, Boris Johnson, to end most mitigation measures in England will test the limits of its mass vaccination campaign.Kazakhstan is awash in fake vaccination passports. The country’s health-care system is one of its most corrupt sectors—a black market is thriving in fake exemption certificates and in forged covid-19 tests showing a negative result. Australia’s covid-19 strategy is being put under strain. Sydney, a city of 5m, is now recording just over 100 new infections a day. By Australia’s previously low rates, that is no joke. The Delta variant combined with a low vaccination rate is causing trouble.India’s economy is suffering from long covid. As a devastating wave of the virus recedes, the effects will linger for much longer.In the Business section, we report on how outbreaks of covid-19 have left South-East Asia with little policy room. A recent surge in cases has knocked economic activity in the region and the return to economic normality will be arduous.Does America face a similar slowdown in economic growth? We argue the Delta variant is by far the biggest of several risks to America’s economy.Our correspondents also discuss the Delta variant on “Money Talks”, our weekly podcast on business and finance. The variant has rattled financial markets but another threat also looms: the end of emergency stimulus. Can the economic recovery survive that? Meanwhile, our data journalists have been looking at what the right and wrong ways are to reduce vaccine hesitancy. It seems more people are willing to get jabbed amid speedy vaccination campaigns—or during surging covid-19 outbreaks.Zanny Minton Beddoes Editor-In-Chief The Economist

Posted in Recensioni/Reviews | Contrassegnato da tag: , , | Leave a Comment »

People who’ve received Pfizer’s COVID-19 vaccine

Posted by fidest press agency su martedì, 20 aprile 2021

They are likely to need a third dose six to 12 months after their first round, the company’s CEO said Thursday.Speaking during a CVS Health Live event that was posted on Facebook, the head of the pharmaceutical corporation, Albert Bourla, said new data shows that Pfizer’s vaccine is effective against a concerning variant of the coronavirus that was first seen in South Africa.”Protection goes down by time but still in six months it’s still extremely, extremely high,” Bourla said. “If you ask me, I think that there will be a need, based on these data, for revaccinations.”It was still unclear how often people would have to receive booster shots, the CEO said, adding that “a likely scenario is that there will be likely a need for a third dose somewhere between six and 12 months and then from there, there will be an annual re-vaccination. But all this needs to be confirmed.” He noted that in a pandemic, “you are as protected as your neighbor.” Font: https://abc7.com/health/third-vaccine-dose-likely-needed-in-6-to-12-months-pfizer-ceo-says/10520223/

Posted in Spazio aperto/open space | Contrassegnato da tag: , , | Leave a Comment »

Caritas Internationalis urges decision to ensure equitable access to the vaccine

Posted by fidest press agency su domenica, 7 febbraio 2021

Caritas Internationalis calls on the United Nations and the international community to take urgent action to deal with the Covid-19 pandemic and the access to the vaccine. In a joint appeal signed by Cardinal Luis Antonio Tagle, President of Caritas Internationalis, Cardinal Peter K. A. Turkson, Prefect of the Dicastery for the Promotion of Integral Human Development, and Aloysius John, Secretary General of Caritas Internationalis, Caritas confederation urges decision makers and the United Nations to call for a Security Council meeting to address access to vaccines as a global security problem, to undertake debt remission of the poorest countries, thus freeing up resources to upgrade their health systems, and to make vaccines more available by promoting local hubs close to the neediest areas. The three also urged rich nations to shun any form of vaccine nationalism and protectionism, saying it would hurt the poorest nations the most. They appealed to political leaders to look beyond the interests of their own nations and see the crisis in the wider context of the global health situation.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Applied DNA and Takis Biotech/Evvivax to Launch Clinical Trial for Veterinary Use of Linear COVID-19 Vaccine Candidate

Posted by fidest press agency su mercoledì, 23 settembre 2020

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, preclinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today announced that it and Evvivax, S.R.L., a spin-out of Takis Biotech focused on engineered veterinary immunotherapy and vaccines, are expected to initiate a veterinary clinical trial of one of the Company’s five LineaDNA™ vaccine candidates upon approval of the clinical plan by the U.S. Department of Agriculture. The goal of the vaccine trial is to evaluate the vaccine candidate as a strategy for the prevention of SARS-CoV-2 (COVID-19) (a zoonotic disease) infections in companion felines of humans. The clinical trial will seek to understand the immune response in cats by utilizing a vaccination strategy of interest in people that could yield valuable data for both cats and humans.
In addition to curbing feline SARS-CoV-2 infections, the vaccine may have a secondary benefit of preventing transfer of the SARS-CoV-2 virus from cats to their human owners. While no such transfer has been formally documented to date, there is still much that is unknown about the disease and its transmission across species. The vaccine trial also serves the additional purpose of generating data on larger animals required as part of the Company’s preclinical development work on its vaccine candidates for potential human development.The clinical trial is a New York State-based, single-center trial that intends to enroll 30 healthy domestic feline companion animals and follow them for six months. The study will evaluate domestic feline immune response, safety, and tolerability of the LineaDNA vaccine candidate, which will be injection once per month at 1mg/month for the first three months of the trial. Dosing will be administered intramuscularly via gene electrotransfer utilizing electroporation technology. The primary endpoint is to determine evidence of antibody and T-cell response in the companion felines.The trial will take place at Guardian Veterinary Specialists in Brewster, N.Y., under the supervision of Dr. Joseph Impellizeri, DVM, DACVIM (O), MRCVS from Veterinary Oncology Services, LLC (link). Applied DNA and Evvivax will co-sponsor the trial. Applied DNA’s participation is approximately $100,000, and the Company will supply a quantity of the linear DNA vaccine candidate.In an article titled ‘Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2’ published in Science Magazine on May 29, 2020, the authors of the article conducted research that found that “in cats the virus replicated in the nose and throat and caused inflammatory pathology deeper in the respiratory tract, and airborne transmission did occur between pairs of cats”.According to the CDC, roughly 60% of human infectious diseases are zoonotic, such as rabies, Lyme disease, West Nile virus, and MERS, among others. Globally and in the United States, COVID-19 positive cats have been reported in small numbers. The World Organization for Animal Health (OIE) indicates that “infection of animals with COVID-19 virus meets the criteria of an emerging disease.”Applied DNA’s LineaDNA vaccine candidates for COVID-19 have previously demonstrated evidence of production of antibody and T-cell responses at low doses of linear DNA in preclinical mouse models. The Company believes that linear DNA vaccines have inherent advantages over conventional DNA and RNA vaccines: they contain only the desired therapeutic DNA sequence with reduced risk of antibiotic resistance and genomic integration; they hold the advantages of speed and scalability when manufactured by the Company’s LinearDNA manufacturing platform; they are manufactured at high levels of purity and with very simple means of production; they are much more stable during storage and shipments than RNA-based vaccines which is a practical advantage during a worldwide deployment.Dr. James A. Hayward, president and CEO of Applied DNA, stated, “Animal health offers an efficient regulatory path with the U.S Department of Agriculture that serves as a second avenue through which to potentially commercialize our linear DNA COVID-19 vaccine development work while having the ancillary benefit of progressing our human related preclinical development work with the data generated from this domestic cat study. Because animals and people can both be affected by this zoonotic virus, and with much of the world’s COVID-19 efforts centered on humans with very little known about its effects on our closest companions with whom we share our homes, we believe it prudent to pursue this avenue for the therapeutic benefit of animals and humans alike.Commenting on the collaboration, Dr. Luigi Aurisicchio, Chief Executive and Scientific Officer of Takis Biotech and Evvivax, said, “The holy grail would be to prevent COVID-19 as opposed to waiting for it to start and then treating it. The implications of success of this cat study would be quite large, both for cats and people.”

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Trials of a vaccine and new drug raise hope of beating covid-19

Posted by fidest press agency su venerdì, 24 luglio 2020

IN EARLY JANUARY researchers at Oxford University started work on a vaccine for covid-19. At that time the illness was a tiny outbreak without a proper name. Six months on, with more than 600,000 people dead, the Oxford team is leading a race to develop a vaccine that could halt the pandemic. The vaccine has been raced into production around the world by AstraZeneca, a British-Swedish drug company, and billions of doses are planned. But two key questions remain: is it safe and does it work? The first glimmers of the answers have just arrived, with the publication in the Lancet on July 20th of a paper about a trial of the Oxford vaccine, which began in April and involved 1,000 volunteers.According to Adrian Hill, director of Oxford’s Jenner Institute and one of the authors of the paper, the new vaccine stimulated a strong immune response and appears to be well tolerated and safe. It generated both antibodies and “an excellent” T-cell response. Antibodies and T-cells are the two principal arms of the immune system. The former recognise, lock onto and disable pathogens. The latter recognise and kill infected body cells, to stop viruses reproducing inside them. Dr Hill says that the antibody levels seen in the trial are similar to those observed in natural infections and that the T-cell responses are “very high”. They are also, he says, “clearly better” than those from another vaccine being developed by Moderna, an American biotechnology firm. (font: The Economist)

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

COVID-19: EU must ensure access to medical gear and future vaccine, MEPs say

Posted by fidest press agency su venerdì, 27 marzo 2020

All the EU internal market tools should be used against the COVID-19 crisis. Price hikes and scams on consumers must be stopped and all must have equal access to a future vaccine.In a letter addressed on Monday to the EU Commission Executive Vice-President Margrethe Vestager (Europe Fit for the Digital Age), Commissioners Thierry Breton (Internal Market) and Didier Reynders (Justice), as well as to the Croatian Presidency of the Council, Parliament’s Internal Market Committee calls for further action to be taken to tackle the COVID-19 crisis.“We must show our citizens that the EU is here when they need it. In this time of uncertainty, we must preserve the achievements of the internal market and consumer protection more than ever and use all available tools to their full extent”, says the letter, signed by Internal Market Committee Chair, Petra de Sutter, on behalf of the committee.In order to prevent a shortage of essential goods, such as food, pharmaceuticals, medical supplies and personal protection equipment, the Commission must monitor any restrictions imposed by member states on the free movement of goods in the internal market and ensure that they respect EU rules, MEPs stress.EU countries should also make sure that professional services, especially in the healthcare, childcare or elderly care sectors in cross-border regions can continue to run.“Joint procurement needs to be strengthened, so that it can be used to purchase the vaccine once it is available, and in order to avoid price speculation and allow for equal access in the European Union”, says the Internal Market Committee.MEPs also call for EU countries to coordinate in using innovative technologies such as 3D printing. “The additive manufacturing sector could provide immediate solutions for hospitals that are experiencing sudden shortages in equipment or limited access to essential pieces for personal protective equipment”, they say in the letter.MEPs urge the EU Commission and national authorities to proactively monitor the market during the crisis to prevent consumers from being harmed due to the COVID-19 situation.They should share information about malpractice, e.g. misleading claims about why prices have increased or coronavirus-related scams, in particular for products that are currently in high demand. A consistent and coordinated approach to tackle the misleading practices of rogue traders is needed, in particular for those selling false medical equipment online, says the committee.Finally, the committee welcomes the Commission’s guidelines on the EU passenger rights regulations and the reference to the travel package rules, which allow passengers to cancel their trips without penalty in such “unavoidable and extraordinary circumstances” and which require tour operators to provide assistance to travellers blocked abroad.

Posted in Estero/world news, Politica/Politics | Contrassegnato da tag: , , , | Leave a Comment »

Sinovac Announces Approval of Varicella Vaccine for Prevention

Posted by fidest press agency su domenica, 29 dicembre 2019

Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the China National Medical Products Administration (NMPA) has approved and issued a Product license for the Company’s varicella vaccine to prevent the varicella-zoster virus in children from 1 to 12 years old. Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, “The approval of our varicella vaccine allows us to provide another high-quality product to address unmet medical needs for the Chinese population. This is the first vaccine product approved by the Chinese government after the issuance and implementation of the Vaccine Management Law in China. Our ability to continue to gain approval for our products since the government issued the Vaccine Management Law and implemented stringent management of the vaccine industry is a testament to the strength of our operations and the quality of our products. Moreover, with approximately 40 countries including varicella vaccines in their government sponsored national immunization programs, we have a positive outlook in our ability to provide varicella vaccines to markets outside of China and generate additional sources of growth.”
Varicella, commonly known as “chickenpox,” is a highly contagious infectious disease caused by the varicella-zoster virus. The disease is spread by direct contact or through respiratory droplets. It is characterized by the appearance on the skin and mucous membranes of successive crops of lesions that are easily broken and become scabbed. Varicella usually affects children and is relatively benign, but complications may arise in the form of pneumonia and encephalitis. After infection, the virus may be reactivated and develop into herpes zoster, commonly known as “shingles,” in older adults.Sinovac’s Varicella Vaccine is derived from Oka strain and performed in the Company’s proprietary Human Diploid Cell. Sinovac completed pre-clinical studies of a human vaccine against varicella and was approved to conduct human clinical trials in October 2015. A phase I clinical trial was conducted and completed in 2016. A phase III efficacy study conducted among 6000 subjects in 2017 shows the protection rate of the vaccine is 87.1%, which was published in Clinical Microbiology and Infection.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

The Vaccine Proves Safe and Activates Immunity to Flu

Posted by fidest press agency su venerdì, 17 febbraio 2012

English: This is CDC Clinic Chief Nurse Lee An...

Image via Wikipedia

Nes Ziona, Israel (PRNewswire)BiondVax Pharmaceuticals Ltd. (TASE: BNDX) today announced positive results from its second Phase II clinical trial (BVX-005) of the Universal Influenza Vaccine (Multimeric-001) developed by Biondvax for improving existing flu vaccines in elderly. The vaccine was found to be safe and well tolerated, and induced robust cellular and humoral immune responses in elderly patients (65+), successfully meeting the primary safety and secondary immunogenicity endpoints. In addition, when given as a primer before boosting with a commercially available seasonal influenza vaccine (trivalent inactivated vaccine, or TIV), Multimeric-001 vaccine enhanced the performance of the TIV by increasing immunity to influenza strains contained in the TIV (“prime-boost” regimen). The Multimeric-001 vaccine improved immunity to influenza in the elderly without the need for any adjuvant. The effectiveness of priming with Multimeric-001 was determined by means of hemagglutination inhibition (HAI) assays. HAI-based immune measures are utilized by US and European regulatory authorities to approve and license existing influenza vaccines.
The elderly are a growing population at high risk for influenza and currently under protected. For example in the US, elderly adults constitute 15% of the population but account for 65% of hospitalizations and 90% of deaths attributable to influenza and its complications. This reflects weakening immune systems and the limited immunity provided to the elderly by TIVs. Indeed, of the approximately 350 million elderly worldwide vaccinated with a seasonal TIV each year (about 70% of the total seasonal flu vaccine market), up to 210 million do not respond sufficiently and are not protected against the strains contained in the TIV. Innovative approaches are urgently required to improve protection against influenza among the elderly and hence, to reduce influenza-related morbidity and mortality and associated high economic burden.
This Phase II trial was a randomized, double-blind, placebo-controlled study in 120 elderly (65+) volunteers conducted at two clinical research centers in Israel – the Hadassah University Hospital in Jerusalem and the Tel Aviv Sourasky Medical Center. In light of the successful conclusion of this second Phase II clinical trial in the elderly in Israel, BiondVax is preparing to conduct a third Phase II trial in the elderly in Europe. This trial is expected to commence in the third quarter of 2012 and to be concluded in the first quarter of 2013.
Biondvax`s estimates regarding the future development of the vaccine and expected trials with respect to the vaccine are forward looking information based on the information that Biondvax has in its possession today pertaining to the potential of the vaccine`s development. These estimates may not be realized, in whole or in part, and/or may be realized differently than estimated, as a result of different factors, including the failure to reach the objectives of the trials and/or schedules and/or to obtain the necessary funding for the continuation of development of the vaccine as well as other factors which are not within Biondvax’s control and the materialization of any of the risk factors detailed in Section 5.27 of Biondvax`s shelf prospectus published on January 17, 2012.
BiondVax Pharmaceuticals (“Biondvax”), a publicly-traded company (TASE: BNDX) based in Nes Ziona, Israel, is developing a proprietary, innovative Universal Influenza (“flu”) Vaccine, the Multimeric-001 vaccine, designed to provide multi-season and multi-strain protection against many human influenza virus strains, including both seasonal and pandemic influenza strains.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Promising Results of Novel Combination Vaccine

Posted by fidest press agency su sabato, 7 gennaio 2012

HIV-Infected T Cell

Image via Wikipedia

Leiden. Preclinical studies of HIV-1 vaccine candidates have typically shown post-infection virologic control, but protection against becoming infected has previously only been reported using less rigorous viral challenges. This proof-of-concept study, which tested MVA, Ad26, and Ad35 vector-based vaccines, is the first to show partial vaccine protection in the stringent animal model involving heterologous, neutralization-resistant SIVmac251 viral challenges in rhesus monkeys. The new Ad26/MVA and Ad35/Ad26 vector-based vaccine regimens resulted in more than 80% reduction in the per-exposure probability of acquisition of infection against repetitive challenges of SIV.Further analysis also provided insights into the immune responses that may correlate with protection, called “immune correlates.” The results show that antibodies to Env (the envelope protein that makes up the outer coat of the virus) correlated with preventing infection, whereas both T cell and antibody responses correlated with control of post-infection viral replication. These distinct correlates likely reflect fundamentally different mechanisms needed to block establishment of infection compared with controlling viral replication after infection. Goudsmit also noted that “we have clearly shown that including Env in the vaccine is beneficial.”These new preclinical findings provide support for advancing the Ad26/MVA prime-boost vaccine candidate into clinical development.The research was supported by the National Institute of Allergy and Infectious Diseases (NIAID); the Ragon Institute of MGH, MIT, and Harvard; and MHRP.
Crucell Holland B.V. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

New Chairman of the Board

Posted by fidest press agency su domenica, 28 giugno 2009

Nyon, Switzerland, Mymetics Corporation (OTCBB:MYMX), announced that its Board of  Directors has named Jacques-Francois Martin as Chairman of the Board, President and CEO, effective July 1, 2009, replacing Christian Rochet who remains as a non executive Director.  Jacques-Francois Martin previously served as CEO of a predecessor company to Sanofi-Pasteur, Pasteur-Merieux where he successfully negotiated with the Government of Canada to acquire Connaught Laboratories.  Jacques-Francois Martin also has held leadership positions with not-for-profit organizations dedicated to the development of vaccines to eradicate disease in both developed nations and third world countries. Jacques-Francois Martin was President of The Vaccine Fund, directing the Fund’s efforts to provide lifesaving vaccines and other immunization support programs to low-income countries, a member of the board of the Global Alliance for Vaccines and Immunization Working Group (GAVI) and a past founding member of the Strategic Advisory Council of the Bill & Melinda Gates Children’s Vaccine Program. This program has since developed to form part of the Gates Foundation. Further, he was a board member from November 1997 to June 2003 of the Board of the International AIDS Vaccine Initiative (IAVI).
About Mymetics In February 2009 Mymetics announced the success of its pre-clinical HIV/AIDS viral challenge prompting the relevant European authorities to authorize the commencement of the Phase I Human Clinical Trials within sixteen days from the initial filing of the application. The proven success of Mymetics’ vaccine in primates could not have been more compelling: the vaccinated group remained resistant to the virus or at a non detectable level, whereas the non-vaccinated group were completely infected. Phase I Human Clinical Trials were initiated in Q4 2008.  Mymetics Malaria vaccine has completed a first round of Human Clinical trial Phases I and II on adults in Switzerland and in the U.K., for testing of the two-antigen formulation. A Phase 1b clinical trial has been launched in Tanzania to extend the protocol to children and teenagers in a naturally endemic area with results expected in Q3/Q4 2009. A new cycle of Phase I and II Clinical trials with all four antigens is scheduled thereafter in Q4/Q1 2010.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »